Ahmad Mattour, MD
Hematology · Detroit, MINPI 1497980635
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $45,872 of the $56,371 with a category attached, or 81.4%. It is spread thinly across 23 manufacturers, the largest accounting for just 20.8%. Reporting peaked in 2022 at $26,086 and has fallen 87.7% since, to $3,218 in 2025. Among hematology clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 91 payments — averaging $619.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$12K
- ADC Therapeutics America, Inc.$10K
- Incyte Corporation$8K
- Karyopharm Therapeutics Inc.$6K
- Pharmacosmos Therapeutics Inc.$4K
- CTI Biopharma Corp.$3K
- plus $14K from 17 others
Across 112 payments — averaging $6953.26 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$423K
- Novartis$102K
- Takeda Pharmaceuticals U.S.A., Inc.$91K
- Otsuka Pharmaceutical Co., Ltd.$58K
- Bristol Myers Squibb$36K
- E.r. Squibb & Sons, L.L.C.$32K
- plus $37K from 5 others
What the payments were for
- Consulting fees$45,87281%
- Speaking & faculty fees$3,2006%
- Travel & lodging$5,1139%
- Food & beverage$2,1764%
- Education$90%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 20 | $11,742 |
| ADC Therapeutics America, Inc. | 6 | $9,714 |
| Incyte Corporation | 10 | $7,556 |
| Karyopharm Therapeutics Inc. | 12 | $6,498 |
| Pharmacosmos Therapeutics Inc. | 10 | $3,953 |
| CTI Biopharma Corp. | 2 | $3,282 |
| GSK | 1 | $3,250 |
| Novartis | 1 | $1,980 |
| E.r. Squibb & Sons, L.L.C. | 5 | $1,786 |
| Janssen Scientific Affairs, LLC | 1 | $1,635 |
| Bristol Myers Squibb | 7 | $1,327 |
| Beigene USA, Inc. | 4 | $940 |
| Daiichi Sankyo Inc. | 2 | $850 |
| AbbVie | 1 | $675 |
| Beigene, Ltd. | 1 | $525 |
| Sobi, Inc | 1 | $200 |
| Beone Medicines USA, Inc. | 1 | $123 |
| Seagen Inc. | 1 | $106 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $90 |
| Exelixis Inc. | 1 | $66 |
| Gilead | 1 | $35 |
| Bayer | 1 | $23 |
| Lilly USA, LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$56,371 in reported general payments places this provider in the 95th percentile of 50 hematology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 44 | $898,155 |
| ImbruvicaIbrutinib | 40 | $632,038 |
| CalquenceAcalabrutinib Maleate | 36 | $421,701 |
| BrukinsaZanubrutinib | 14 | $194,281 |
| Lenalidomide | 13 | $152,171 |
| VenclextaVenetoclax | 11 | $34,935 |
| EliquisApixaban | 16 | $11,778 |
| Imatinib Mesylate | 11 | $2,301 |
| Hydroxyurea | 23 | $516 |
| Dexamethasone | 24 | $261 |
| Acyclovir | 18 | $116 |
| Prednisone | 11 | $45 |
| Montelukast Sodium | 11 | $30 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $1,327 | $898,15544 claims |
| AstraZenecaCalquence | $11,742 | $421,70136 claims |
| Beigene USA, Inc.Brukinsa | $940 | $194,28114 claims |
| AbbVieVenclexta | $675 | $34,93511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 50 hematology providers in Michigan.
Other hematology in Detroit
- Asif AlaviDetroit$17K
- Paul SwerdlowDetroit$14K
- Andrew KinDetroit$9K
- Maria DiabDetroit$4K
- Hiba Jabbour-AidaDetroit$1K
- Craig ColeLansing$159K
- Matthew PiankoAnn Arbor$51K
- Sami MalekAnn Arbor$49K
- Yasmin KarimiAnn Arbor$47K
- Kristen PettitAnn Arbor$45K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.